Devazepide is a non-peptide CCK (cholecystokinin) receptor antagonist. CCK is a neuroendocrine peptide described to play an important role in cell growth, cell proliferation, and other biological functions. Studies indicate that Devazepide induces apoptosis in Ewing tumor growth studies, and does not reverse the blocking affect of IL-1β in rat studies. In addition, Devazepide has been reported to inhibit the growth of HT29-S-B6 cells and affect the cells morphology.
